SCHEMBL3009728

SCHEMBL3009728

COc1ccc(S(=O)(=O)N2CCN(c3nc(-c4cc(OC)c(OC)c(OC)c4)cs3)CC2)c(OC)c1

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.57
MAPK1 P28482 5/20 0.57
GAA P10253 2/20 0.57
MAPT P10636 10/20 0.55
HSD17B10 Q99714 3/20 0.55
USP2 O75604 1/20 0.55
RECQL P46063 1/20 0.55
POLB P06746 1/20 0.51
TP53 P04637 2/20 0.48
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
LMNA P02545 6/20 0.46
TDP1 Q9NUW8 1/20 0.46
SMN1; SMN2 Q16637 5/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
KMT2A Q03164 4/20 0.46
MEN1 O00255 2/20 0.46
HTT P42858 2/20 0.45
HPGD P15428 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3652234 0.92 ALDH1A1 (0.49) ALDH1A1MAPK1GAAMAPTHSD17B10
SCHEMBL3009767 0.92 ALDH1A1 (0.57) ALDH1A1MAPK1GAAMAPTHSD17B10
SCHEMBL3009594 0.92 MAPT (0.59) ALDH1A1MAPK1GAAMAPTHSD17B10
SCHEMBL3014348 0.91 POLB (0.59) ALDH1A1MAPK1GAAMAPTHSD17B10
SCHEMBL3014451 0.90 MAPT (0.55) ALDH1A1MAPK1GAAMAPTHSD17B10
SCHEMBL3007685 0.90 MAPT (0.59) ALDH1A1MAPK1GAAMAPTHSD17B10
SCHEMBL3019637 0.90 MAPT (0.54) ALDH1A1MAPK1GAAMAPTHSD17B10
SCHEMBL3016261 0.90 MAPT (0.61) ALDH1A1MAPK1GAAMAPTHSD17B10
SCHEMBL3019064 0.89 MAPT (0.61) ALDH1A1MAPK1GAAMAPTHSD17B10
SCHEMBL3012508 0.89 MAPT (0.70) ALDH1A1MAPK1GAAMAPTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA ALDH1A1 3510/4885MAPK1 2767/4885GAA 110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.